idiopathic thrombocytopenic purpura
- Business
Positive Results From ProDERM Study of octagam® 10% in Patients With Dermatomyositis Meeting the Primary Endpoint Will Be Presented at ACR Convergence 2020
LACHEN, Switzerland: Octapharma announces that the final results from the phase III ProDERM study will be presented at the American…
Read More »